Skip to main contentAI and Advanced
/
SUPRIYA · NSEMarket ticker unavailable · configure an authorised index feed
SU
NSE · Equity shares · Biotechnology & Drugs-2.50 · -0.29%
Supriya Lifescience SUPRIYA
NSE:INR 871.5
BSE:INR 882.05
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for SUPRIYA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 874
Day rangeINR 845.55 — INR 889.45
52-week rangeINR 545.5 — INR 1,085
Volume1.92 L
Market cap7,114.93
P/E21.63
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)827.88
Net Income (INR Cr)209.12
Rev Growth (5 Year %)16.52
EPS Growth (5 Year %)11.05
P/E Ratio21.63
Book Value148.66
EPS26.02
Price/BV5.86Computed
Research path: Interpret Supriya Lifescience's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SUPRIYASupriya Lifescience1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,357.11 | 1,112.31 | 921.24 |
| Cash Equivalents | 37.55 | 11.22 | 28.14 |
| Other Liabilities Total | 1.9 | 1.32 | 0.8 |
| Accrued Expenses | 1.67 | 1.19 | 0.37 |
| Common Stock Total | 16.1 | 16.1 | 16.1 |
| Other Current Assets Total | 73.82 | 27.76 | 20.36 |
| Total Assets | 1,357.11 | 1,112.31 | 921.24 |
| Current Portof LT Debt/Capital Leases | 0.25 | 0.32 | 0.47 |
| Total Equity | 1,197.73 | 996.76 | 815.37 |
| Long Term Investments | 98.52 | 63.24 | 63.8 |
| Retained Earnings(Accumulated Deficit) | 1,181.64 | 980.66 | 799.27 |
| Total Common Shares Outstanding | 8.05 | 8.05 | 8.05 |
| Tangible Book Valueper Share Common Eq | 148.66 | 123.68 | 101.1 |
| Total Liabilities | 159.37 | 115.55 | 105.87 |
| Total Debt | 5.44 | 5.38 | 5.49 |
| Short Term Investments | 41.32 | 61.18 | 39.51 |
| Cashand Short Term Investments | 78.87 | 79.87 | 79.47 |
| Total Receivables Net | 220.02 | 191.48 | 168.1 |
| Deferred Income Tax | 31.24 | 27.02 | 23.15 |
| Accounts Receivable-Trade Net | 219.45 | 134.36 | 111.68 |
| Property/Plant/Equipment Total-Net | 723.39 | 599.49 | 457.3 |
| Total Current Liabilities | 121.04 | 82.16 | 76.89 |
| Total Inventory | 159.6 | 127.69 | 118.65 |
| Accounts Payable | 110.85 | 74.55 | 59.57 |
| Other Currentliabilities Total | 8.28 | 6.1 | 16.49 |
| Total Long Term Debt | 5.19 | 5.06 | 5.02 |
| Intangibles Net | 1.31 | 1.39 | 1.66 |
| Other Long Term Assets Total | 1.58 | 11.15 | 0.68 |
| Total Current Assets | 532.3 | 437.04 | 397.8 |
| Capital Lease Obligations | 5.19 | 5.06 | 5.02 |
| Accumulated Depreciation Total | Not available | -78.76 | -58.73 |
| Long Term Debt | Not available | 0 | 0 |
| Prepaid Expenses | Not available | 10.24 | 11.23 |
| Cash | Not available | 7.47 | 11.82 |
| Property/Plant/Equipment Total-Gross | Not available | 530.23 | 367.21 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Other Equity Total | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.08
Price to Sale Ratio8.59
Growth
Debt 5Yr CAGR %-40.39
Margins
Operating Margin 12m32.03
Operating Margin 5y Avg31.9
Net Profit Margin 12m25.26
Net Profit Margin 5y24.56
Yield
Dividend Yield %0.11
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.65
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 68.30%
- FII
- 6.18%
- MF
- 1.29%
- Other
- 24.23%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 19 November 2025Market news · 19 Nov 2025, 6:39 am
Sumeet Bagadia recommends five breakout stocks to buy today - Faze Three, SeQuent Scientific, Control Print, Anand Rathi Share and Stock Brokers, and Supriya Lifescience.
Wockhardt, Sun Pharma, Lupin, Alembic Pharma, other pharma stocks rebound up to 10% after clarification on Trump TariffsMarket news · 29 Sept 2025, 11:30 am
Shares of Wockhardt rallied over 10%, leading the recovery in the sector. Bajaj Healthcare, Supriya Lifescience, Alembic Pharmaceuticals, Aster DM Healthcare, Sun Pharmaceutical Industries, Lupin, Cipla, Aarti Drugs, Zydus Lifesciences, Biocon, and others gained between 1–3%.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 3 April 2025Market news · 3 Apr 2025, 6:40 am
Sumeet Bagadia recommended buying these seven breakout shares to buy today - Nalwa Sons Investments, Supriya Lifescience, KPR Mill, Godawari Power and Ispat, and Shyam Metalics and Energy.
Supriya Lifescience share price skyrockets 8% to 52-week high: Nearly doubles in a year as Europe sales gain tractionMarket news · 19 Aug 2024, 4:36 pm
Stock Market Today: Supriya Lifescience share price rises 8% to 52-week high during the intraday trades. The stock that closed at ₹ 532.15 , up 4.36% has almost doubled in a year. Rising Developed market sales are driving growth, Check for details-
Corporate actions
Events
- annual General MeetingPOM
- dividendRs.1.0000 per share(50%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.0000 per share(50%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Supriya Lifescience
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 API products that offer remedies in therapeutic segments, such as antihistamines, analgesics, vitamins, anesthetics and anti-asthmatics, among others. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulfate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others. The Company has manufacturing facilities located in Maharashtra.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SUPRIYA
- BSE Code
- 543434
Questions
Stock FAQ
What is the symbol and ISIN of Supriya Lifescience?
Supriya Lifescience has the symbol SUPRIYA and ISIN - INE07RO01027.
What is the current price of Supriya Lifescience?
Supriya Lifescience is currently trading at INR 871.50.
What are the year high and year low of Supriya Lifescience?
Supriya Lifescience has a year high of INR 1,085.00 and a year low of INR 545.50.
What is the market capitalization of Supriya Lifescience?
Supriya Lifescience has a market capitalization of INR 7,114.93 crore.
What is the P/E ratio of Supriya Lifescience?
Supriya Lifescience has a P/E ratio of 21.63.
What is the dividend yield of Supriya Lifescience?
Supriya Lifescience has a dividend yield of 0.11%.
How is the financial performance of Supriya Lifescience based on revenue, net income, and EPS?
Supriya Lifescience has revenue of INR 827.88 crore, net income of INR 209.12 crore, and EPS of INR 26.02.
What is the book value of Supriya Lifescience?
Supriya Lifescience has a book value of INR 148.66.
What is the debt-to-equity ratio of Supriya Lifescience?
Supriya Lifescience has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Supriya Lifescience?
Supriya Lifescience has a price-to-book ratio of 5.86 and a price-to-sales ratio of 8.59.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.